Ambry Genetics Leading the Way With Clinical Next-Generation Sequencing


Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

In early March, Ambry Genetics (Aliso Viejo, Calif.) reached the milestone of having
sequenced 10,000 clinical diagnostic samples with next-generation sequencing (NGS)
and processed 100,000 total NGS samples. Ambry has a proud history of being on the
forefront of genetic testing, having been among the first purchasers of commercially
available sequencing instruments back in 2007. The company says it was the first to offer
an NGS-based diagnostic test in April 2010, with the introduction of its 81-gene panel
for X-linked intellectual disability. Ambry continued with its list of firsts by launching
the first clinically available whole-exome sequencing test at a CLIA-certified laboratory
in 2011.

Evolving from its roots in cystic fibrosis (CF) testing, Ambry continues to develop and
enhance its comprehensive testing menu with significant investments in automation.
This has allowed the company to focus on reducing test turnaround time while retaining
its focus on quality client service and steadfast attention to their guiding ethical
principles. Recently, Ambry CEO Charles Dunlop spoke to DTTR about the evolution of NGS in
clinical care and Ambry’s commitment to rapid, yet responsible, growth in the future.

Read Full Article Here

About Ambry Genetics ®

Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer the most comprehensive genetic testing menu in the industry. Ambry is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. As part of the Konica Minolta family, Ambry is responsibly applying new technologies to the clinical molecular diagnostics market to bring about precision medicine. For more information about Ambry Genetics, visit

Press Contact:
Dina Scaglione
Director, Marketing
949 457 4355

Search Results

Start your search...